XClose

UCL Institute for Liver & Digestive Health

Home
Menu

Research Activity & Research Groups

The UCL Institute for Liver & Digestive Health (UCL-IL&DH) is a major education site in the area of Liver and Digestive Medicine and provides training for UCL medical students, specialist registrars, graduate students and post-doctoral fellows from the UK, from other EU Countries and from the rest of the World, including developing Countries.

Clinical Activities

This makes the UCL-IL&DH one of the most international and multicultural clinical research hubs in the World. Research activities are characterized by a strong integration of clinical activities with laboratory expertise and biotechnological platforms which span from very basic cellular and molecular biology to translational projects in Hepatology, Gastroenterology, HPB, Liver Transplant and Regenerative Medicine. 

Currently most of the academic and clinical activities of the UCL-IL&DH are based at the Royal Free Campus in Hampstead; the Royal Free Hospital being one of the largest Foundation NHS Trusts in the United Kingdom.

Our Mission

In addition, the UCL-IL&DH represents one of the major academic centres within the clinical consortium UCL-Partners (UCLP), whose mission is to develop and implement an extensive network of clinical excellence in North-East London.

The UCL-IL&DH is a major education site in the area of Liver and Digestive Medicine and provides training for UCL medical students, specialist registrars, graduate students and post-doctoral fellows from the UK, from other EU Countries and from the rest of the World, including developing Countries.

This makes the UCL-IL&DH one of the most international and multicultural clinical research hubs in the World.

Research Groups within ILDH

Alcoholic Liver Disease - Genetic and Metabolic Aspects

Principal Investigator:  Dr Marsha Morgan
Members:  
Michael J Way PhD Fellow
William McCabe PhD Fellow
Adina Nash PhD Fellow
Catherine Fennessy MSc Student  

Research interests:

  • Identification of the genetic factors responsible for the development of alcohol dependence through, associational and GWAS studies
  • Determination of the interaction between the genes associated with alcohol dependence and Axis 1 psychiatric illness
  • Delineation of the genetic predisposition to alcohol-related cirrhosis through GWAS, whole exome and whole genomic studies
  • Structural and functional studies of Ile148Met PNPLA3 - a genetic variant responsible for 30% of the variance in development of significant alcohol-related liver injury
  • The genetic predisposition to develop khat-related hepatotoxicity
  • Disruption of electrophysiological variables in patients with cirrhosis
  • Signal processing of electrophysiological systems variables
  • The activity of the ion channels, energy-dependent pumps and ion exchange processes in patients with alcohol-related peripheral neuropathy
  • Body composition and compartmental shifts in patients with cirrhosis
Lipid and Membrane Biology

Principal Investigator:    Dr Shane Minogue
Members: 

Mr David Brown

Mrs Ruth Jacobs

Mr Ganiyu Olabanji Alli-Balogun, PhD student

Mr Daniel Janman, BBSRC CASE, PhD Student

Research interests:

  • Phosphoinositide lipids and membrane dynamics.
  • Oncogenic signalling from endosomal compartments.
  • Membrane re-organisation during cytokinesis.
  • Phosphoinositides in disease.


Principal Investigator: Dr Mark Waugh
Research interests:

  • Cellular membrane organization and lipid rafts
  • Lipid droplet biogenesis
  • Crosstalk between different lipid metabolic pathways
  • Phosphoinositide signalling in disease
Liver Failure

Principal Investigator:  Professor Rajiv Jalan
Members:   
Dr Danielle Adebayo, PhD Student/Clinical Research Fellow
Dr Marc Oria, Post Doctoral Research Fellow
Dr Fausto Andreola, Post Doctoral Research Fellow
Dr Azin Farzan Amiri, PhD Student
Ms Ana Hadjihambi, PhD Student
Dr Jane Macnaughtan, PhD Student/Clinical Research Fellow


Principal Investigator:  Dr Raj Mookerjee
Members: 
Dr Helen Jones, Post Doctoral Research Fellow
Dr Manil Chouhan, PhD Student, Wellcome Trust Fellow
Dr Gautam Mehta, PhD Student, Wellcome Trust Fellow
Dr Graziella Privaterra, Clinical Fellow Attachment

Principal Investigator:  Dr Nathan Davies
Members:
Ms Abeba Habtesion, Technical Officer
William Ashworth, PhD Student

Research interests of the Liver Failure Group:

  • Chronic liver disease due to alcohol, viral hepatitis and obesity, is the 5th commonest cause of death in the UK, with liver mortality rising 6-fold since 1970 while relative mortality from cardiovascular disease, stroke and respiratory disease has fallen. Chronic liver disease is often asymptomatic until severe complications develop and so better diagnostic tests are required. Furthermore there are very few effective treatments for the complications of cirrhosis and liver failure.
  • The Liver Failure Group was established in 2000 with the aim to improve the survival of patients with cirrhosis through development of novel strategies for early diagnosis, prevention of complications and effective management of patients with liver failure and liver transplantation. We hypothesize that superimposed inflammation on the background of cirrhosis critically alters end-organ function resulting in ACLF. Our research programs focus on the complex relationships between inflammation, function and disease. It reflects a truly translational pathway from epidemiology through pathophysiology to the development of novel biomarkers and effective intervention. The principle investigators collaborate widely both within UCL and with research groups and industrial partners around the world in order to further the program goals.

General Aims:

  • The aims of our on-going studies are to investigate the molecular basis of altered host response to injury in liver disease and its relationship with organ function and, use this knowledge to propose novel prognostic markers and therapeutic interventions.

Specific Aims:

  • Develop novel biomarkers for early diagnosis of cirrhosis and prognostic models.
  • Develop novel strategies for treatment of complications of cirrhosis and liver failure.
  • Development of novel strategies for improving outcome of liver transplantation and liver surgery.

Knowledge Transfer:

  • The studies have led to the filing of 13 linked, patents by UCL, successful licensing of a novel drug for the treatment of hepatic encephalopathy and a license of 5 of the inventions in a new UCL spin-out company, Yaqrit limited.

The following research programs are currently running in the laboratory:

  • Biomarkers.
  • Studies into the pathophysiological basis of ACLF have led to the development of DASIMAR (Mookerjee, Jalan, and Davies), a novel biomarker combining dimethylarginines and modified albumin to prognosticate on patients with acute deterioration of cirrhosis.
  • Studies into the mechanisms of infection and inflammation in cirrhosis has led to development of novel test involving testing Neutrophil function (planned) to select patients with alcoholic hepatitis for steroid therapy (Jalan, Mookerjee) which is planned to be tested in clinical studies.
  • Links with the imaging group has led to the development of novel protocols for measuring hepatic artery and portal vein flow to generate algorithms to predict severity of portal hypertension (Mookerjee, Davies, Jalan – with Prof. Stuart Taylor  & Dr Shonit Punwani - Centre for Medical Imaging ).
  • Studies in models of ACLF and hepatorenal syndrome (Jalan) have led to the identification that the kidneys in this syndrome are not normal and that there is evidence of kidney injury. This has resulted in the discovery of novel biomarker urinary toll-like receptor-4 and potential novel therapy.
  • Drugs and Devices.
  • Novel approach to treatment of hyperammonemia and hepatic encephalopathy was conceptualised and developed targeting multiple organs, ornithine phenyl acetate (Jalan, Davies) which has been licensed to Ocera Therapeutics, and is entering Phase 2a clinical trials.
  • Our recent observation that Glutamine synthase is deficient in Cirrhosis has led to the development of a gene therapy approach to replacing GS (Jalan).
  • Studies into intrahepatic resistance of cirrhosis have identified DDAH and asymmetric dimethylarginine as a potential novel target to treat portal hypertension (Mookerjee, Jalan) and novel genetic strategies to augment (AAV) or regulate DDAH1 transcription (ASO) have been developed to lower hepatic ADMA (Mookerjee).
  • Proof of concept in models has been achieved and clinical studies are planned. Studies in animal models have shown that the Farsenoid X receptor antagonist (INT-747, Intercept Pharma) reduces portal pressure and a Phase 2 clinical study is underway (Mookerjee).
  • In ACLF, an inappropriately activated sympathetic nervous system was identified as being causally associated with severity of portal hypertension and renal dysfunction leading up to the concepts for development of alpha-2a antagonists for treatment. Studies in animal models have led to a drug development programme (Mookerjee with Prof David Selwood, WIBR).
  • Treatment of liver failure is being developed modulators of inflammation targeting the toll-like receptor 4 pathway to prevent activation through the damage associated or the pathogen associated molecular patterns (toll-like 4 antagonists) for the treatment of acute liver failure and hepatorenal syndrome (Jalan, Mookerjee, Davies). Proof of concept has been achieved.
  • We have developed and artificial liver support device using strategies that target albumin exchange and endotoxin ligation (ARSeNEL) (Davies, Jalan).
  • Development of novel extracorporeal devices specifically targeting modulators of inflammation and oxidative stress (Davies).
  • In order to reduce the increased gut translocation in cirrhosis, we have shown that administering oral nanocarbons with macrospherical binding domains in animal models reduces bacterial translocation and is a potential therapy for prevention and treatment of complications of cirrhosis, NALFD and alcoholic liver disease (Jalan, Davies, Mookerjee).
  • We have shown that TLR 7 and 9 are potential novel target for the treatment of Hepatocellular carcinoma. We believe that chloroquine may well be a drug that will prevent occurrence of hepatocellular carcinoma (Jalan).

Industry Funded Clinical Studies:

  • An industry funded Phase 3 study of a novel implantable pump (Sequana Medical) is being planned for the treatment of refractory ascites (Jalan).
  • The Phase 2b study of the first novel therapeutic for the treatment of acute on chronic liver failure is due to start (Conatus Pharma) (Jalan/Mookerjee).
  • A study of a novel bioartificial liver support device for the treatment of alcoholic hepatitis and acute on chronic liver failure is due to start (Jalan/Agarwal/Mookerjee).

Group interests schematic
Tissue Engineering: Liver Cells for Therapeutic Use

Principal Investigator: Professor Clare Selden
Members:
Humphrey Hodgson, Emeritus Professor
Barry Fuller, Professor in Surgical Science & Low Temperature Medicine
Eloy Erro, Senior Research Assistant
Aurelie LeLay, Research Assistant
Dimitrios Airantzis, PhD Student
Sherri-Ann Chalmers, Senior Medical Technical Officer
 

Research interests:

  • Harnessing the hepatocyte for therapeutic use
  • Development of a bioartificial liver machine
  • 3-dimensional mammalian cell culture
  • Cryopreservation of 3-dimensional cell spheroids
  • Pathogen reduction technology
  • Liver cell biology
  • Gene therapy
  • Liver Regeneration
  • Tissue engineering
Metabolic Liver

Principal InvestigatorDr Jude Oben, MD, PhD, FRCP
Members:
 

Research interests:

  • Autonomic Nervous System and Cellular Mechanisms in Acute and Chronic Liver Injury-Repair
  • Circadian Rhythms Disruptions and Molecular Mechanisms of Injury-Repair in NAFLD and other liver diseases
  • Fibrotic Mechanisms in Inflammatory Bowel Disease


Principal Investigator:  Dr James Dooley            
Research interests:

  • Wilson’s Disease
  • Non-alcoholic fatty liver disease (NAFLD)


Principal Investigator: Dr Emmanuel Tsochatzis
Members:
Elena Buzzetti, Research Fellow
Maria Kalafatelli, Research Fellow

Research interests:

  • Non-invasive assessment of liver fibrosis.
  • Quantification of liver fibrosis using collagen proportionate area in patients with NAFLD.
  • Establishing referral pathways for patients with NAFLD.
Fibrosis/Cirrhosis and Regeneration

Principal Investigator: Professor Massimo Pinzani MD PhD
Members:    
Dr Rajai Al-Jehani PhD, Biomedical Scientist & Honorary Senior Research Associate
Dr Giuseppe Mazza MBs, PhD

Research interests:

  • Tissue engineering and whole organ regeneration, Disease modelling using 3 dimensional biological scaffold, iPSC biology
  • 3D biology of hepatic fibrosis and metabolism of fibrotic tissue
  • Molecular genetics of hepatocellular carcinoma and identification of novel targets for diagnosis, management and treatment of liver cancer.
  • Portal hypertension, Inflammatory markers and immune response in chronic liver disease, hepatic encephalopathy, Imaging in liver disease
  • Use of bile acids agonists for the treatment of liver- and gastrointestinal diseases.
  • Pathogenesis of intestinal fibrosis in IBD


Members:               
Professor Owen Epstein, Professor Gastroenterology
Dr Emmanuel Tsochatzis, Senior Lecturer & Honorary Consultant
Dr David Patch, Consultant Physician
Dr Bambos Charalambous, Senior Lecturer in Microbiology
Dr Eleni Theorididou, Research Fellow
Professor Amar Dhillon, Professor of Histopathologist
Dr Tu Vinh Luong, Consultant Histopathologist
Dr Pratima Choudary, Consultant Haematologist
Dr Malika Sekhar, Consultant Haematologist
Dr Barry Hogan, Research Fellow
Dr Bhagani Aggarwal, Consultant Intensivist
Dr Dominic Yu, Consultant Radiologist
Dr Neil Davies, Consultant Radiologist

Research Interests:

  • Evaluation of non invasive tests of fibrosis- cost effectiveness    
  • Calibration of NITs with quantitative evaluation of hepatic fibrosis
  • Evaluation of  histological sub-classification of cirrhosis
  • Evaluation of HVPG and quantitative collagen estimation in cirrhosis
  • Evaluation of the effect of immunosuppressive regimens on post transplant hepatitis C fibrosis
  • Prognostic assessment of emergency TIPS
  • Anti coagulation in splanchnic thrombosis
  • RCT of Danis stent for bleeding oesophageal varices
  • Adrenal function correction in cirrhosis: unresponsive hepatorenal syndrome, post   TIPS for ascites, prolonged QT interval, sepsis and liver transplantation
  • Prognostic models in ITU for cirrhotics
  • Preventative trials in cirrhosis
  • Bowel motility, permeability and bacterial translocation  


Principal Investigator:     Professor Kevin Moore MD
 

Research Interests:

  • Alcohol- and lipotoxicity-induced hepatic fibrosis
  • Redox regulation of vascular function in liver disease


Principal Investigator:     Dr Krista Rombouts PhD, Professorial Research Associate
Members:  
Dr Katrin Böttcher MD, PhD

Darek Lachowski MBs, PhD Student to Dr Krista Rombouts & Dr Armando Del Rio Hernandez, Department of Bioengineering, Imperial College London

Research interests:

  • Discovery and characterization of novel signalling pathways between tumour and fibrotic stroma cells to prevent primary and secondary liver cancer in a fibrotic/cirrhotic liver.
  • Identification of new drug targets for antifibrotic and anticancer therapy.
  • Role of innate and acquired immunity in fibrogenesis.   


Principal Investigator: Prof Justin Hsuan
Members: 
Dr Nick Hamilton MD, MRC Clinical Research Training Fellow with Professor Janes

Dr Xiaoping Huang MD, Visiting Researcher

Dr Joy Cuenco PhD, Postdoctoral Fellow

Dr Xiufang Lyu

Ms Mariya Semkova, PhD student
 

Research Interests:

  • Matrisomal transformation in chronic liver disease
  • Comparative proteomics of tissue fibrosis
  • Stem cell and scaffold engineering in regenerative medicine
  • Neuroendocrine tumour biomarkers and signalling


Principal Investigator: Dr Emmanuel Tsochatzis
Members:
Elena Buzzetti, Research Fellow
Maria Kalafatelli, Research Fellow

Research interests:

  • Evaluation of the effect of immunosuppressive regimens on post transplant hepatitis C fibrosis.
  • Bowel motility, permeability and bacterial translocation in cirrhosis.
  • Adrenal insufficiency in cirrhosis.
  • Evaluation of non-invasive tests of fibrosis, meta-analysis of diagnostic accuracy and cost-effectiveness.   
  • Calibration of NITs with quantitative evaluation of hepatic fibrosis and clinical outcomes.
  • Histological sub-classification of cirrhosis using collagen proportionate area.
  • Evaluation of HVPG and quantitative collagen estimation in cirrhosis.
Hepatobiliary and Pancreatic Cancer
Principal Investigator:

Prof Stephen Pereira, Professor of Gastroenterology & Hepatology

Group Members:

Dr Pilar Acedo Nuñez, Post-Doctoral Research Fellow
Ms Ponni Balasundaram, Clinical Data Manager
Dr George Goodchild, Clinical Research Fellow
Dr Geri Keane, Clinical Research Fellow
Mr Peter Labib, Clinical Research Fellow, PhD student
Ms Khadra Mohamoud, Clinical Data Manager
Ms Safreena Nazir, Clinical Data Manager
Mr Alexander Ney, Clinical Research Fellow, PhD student

Research interests:

Clinical

  • Cystic tumours of the pancreas
  • Confocal endomicroscopy
  • Endoscopic tumour ablation
  • Patient perception studies
  • Hereditary pancreatitis and familial pancreatic cancer
  • Surveillance strategies
  • Patient perception studies
  • Pancreatic cancer
  • Non-invasive screening tool development

Translational

  • Cholangiocarcinoma (bile duct cancer)
  • Serum proteomics
  • Serum and tissue biobank collection
  • IgG4-related pancreatobiliary disease
  • Serum and tissue biobank collection
  • Imaging studies

Pancreatic cancer

  • Biomarker discovery for early diagnostics
  • Biomarkers as surrogate markers for treatment response
  • Serum, tissue and urine biobank collection
  • Biophotonics for diagnostics and image-guided surgery
  • Nanoparticle diagnostics and drug delivery
  • Scaffold and organoid development
  • Light based therapies

Pancreatic neuroendocrine tumours (PNETs)

  • Scaffold and organoid development
  • Biomarker discovery for early diagnostics
  • Biomarkers as surrogate markers for treatment response
UCL Collaborations:

Dr Dean Barratt - Centre for Medical Image Computing (CMIC)
Prof Brian Davidson - Division of Surgery & Interval Science
Prof John Bridgewater - Department of Oncology
Mr Kito Fusai - Consultant HPB Surgeon, Royal Free Hospital
Prof Justin Hsuan - Institute for Liver & Digestive Health
Prof Sandy Macrobert - Division of Surgery & Interval Science
Prof Massimo Pinzani - Institute for Liver & Digestive Health
Prof Hans Stauss - Institute of Immunology & Transplantation
Dr John Timms - Institute for Women's Health
Dr Tom Vercauteren - Centre for Medical Image Computing (CABI)

UK Collaborations:

Dr Bart Cornelissen - Department of Oncology, Oxford University
Prof Eithne Costello-Goldring - Institute of Translational Medicine, University of Liverpool
Dr Tatjana Crnogorac-Jurcevic - Barts Cancer Institute, Queen Mary’s University London
Dr Bill Greenhalf - Institute of Translational Medicine, University of Liverpool
Prof Eric O’Neill - Institute for Radiation Oncology, Oxford University

International Collaborations:

Prof Alfredo Carrato - Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain
Prof Tayyaba Hasan - Massachusetts General Hospital, Boston, USA
Dr Nuria Malats - Centro Nacional de Investigaciones Onológicas (CNIO), Madrid, Spain
Dr Diana Puente - IDIAP Jordi Gol, Barcelona, Spain
Dr Rosalie Sears - Oregon Health & Science University (OHSU), Portland, USA
Dr Brett Sheppard - Oregon Health & Science University (OHSU), Portland, USA
Prof Carlo La Vecchia - University of Milan, Italy

Group memberships:

EUPancreas (Integrated European Platform for Pancreatic Cancer Research)
(IPSCSG) International PSC Study Group
UK-PSC Consortium

Industry Collaborations:

Immunovia AB - Lund, Sweden
Nanoco Technologies Ltd., Manchester, UK

 

 

Principal Investigator:  Professor Brian Davidson

Members:
Prof Barry Fuller
Prof Alex Seifalian
Prof David Hawkes
Prof Nader Saffari

Lecturer:
Mr Kurinchi Gurusamy
CRF PhD/MD:
Hamid Abudhaise
Ali Jomaa
Rajarajan Ramamoorthy
Francis Robertson
Crispin Schneider
Pulathis Siriwardana

Research interests:
•    Image guided laparoscopic liver surgery
•    Development of instrumentation for liver surgery
•    Liver tissue engineering
•    Liver ischaemia-reperfusion injury
•    Organ preservation for transplantation
•    Machine perfusion
•    Remote ischaemic preconditioning
•    HIFU for cancer treatment
•    Immunological responses in pancreas cancer
•    TROPS - Tumour Research Organ Perfusion System
•    Evidence based healthcare and meta-analysis

Viral Hepatitis

Principal Investigator: Professor William Rosenberg


Group Members: 
Dr Julie Parkes, Honorary Senior Lecturer
Dr Michael Whelan, Head of Research, iQur Limited
Ms Harsimran Singh, Research Fellow
Dr Ankur Srivastava, Clinical Research Fellow
Dr Kam Zaki, Clinical Research Fellow
Dr Douglas Macdonald, MRC Clinician Scientist
Dr Brian Hogan, Clinical Research Fellow
Dr Sudeep Tanwar, Clinical Research Fellow
Dr Paul Trembling and Anita Roddick, Clinical Research Fellow
Ms Carmen Velazquez, Research Nurse
Ms Lesley Winter, Research Nurse
Ms Melrose Browne-Morgan, Research Coordinator
Ms Ruth Ochuma, Research Assistant


Research interests:

  • Vaccines
  • Immune responses to viral hepatitis and liver fibrosis
  • Biomarkers of liver fibrosis
  • Clinical trials of therapies and tests in chronic liver disease


The Group’s work is focused on viral hepatitis and liver fibrosis, encompassing laboratory based basic science, clinical trials and health services research.
 

Laboratory Based Basic Science
Hepatitis B Tandem Core Vaccine Platform: With iQur Limited we are conducting a program of research to develop vaccines for pandemic influenza and malaria using virus like particles formed from stabilized Hepatitis B core proteins. 

The Group leads a consortium that won £3.8 million funding from the EU Framework 7 Program to develop a universal influenza vaccine. In 2013 we successfully applied to the TSB-MRC Biocatalyst Fund to apply the Tandem Core platform to malaria in collaboration with Prof Adrian Hill at the Jenner Institute, University of Oxford.

Funding from the TSB also supports a joint program with DTRA developing vaccines for Burkholderia.

Lentiviral Vaccines for Viral Hepatitis: In collaboration with Prof Mary Collins we are investigating the use of lentiviral vectors incorporating adjuvants to generate prophylactic and therapeutic vaccines. In 2013 we will apply the lentiviral vaccine platform to cancer therapy in collaboration with Prof Daniel Hochhauser.

Immune influences on liver fibrosis: The immune and inflammatory responses triggered by viral infection are thought to be central to the liver damage in chronic hepatitis B and C. Working with Prof Mala Maini we are investigating the interaction between virus-specific and innate immune responses and liver fibrosis.
 

Biomarkers of chronic liver disease
Biomarker Application: Over the last 15 years the Group has worked on the identification and validation of biomarkers of liver fibrosis culminating in the discovery and clinical development of the Enhanced Liver Fibrosis Test.

The main focus of the Group in this field is now on the application of the ELF Test in clinical pathways of care. We are investigating the impact of non-invasive tests for liver fibrosis on the detection and management of chronic liver disease.

Studies address the use of testing to detect fibrosis in “at-risk” populations; the use of tests to stratify patients for referral from primary care to appropriate services; the use of testing to enforce adherence in behaviour modification programmes; and the use of testing to guide management of chronic disease in secondary care. The latter includes the NIHR Applied Programme Grant funded randomized controlled trial, ELUCIDATE.

These studies incorporate a range of research methods including health economics and epidemiology. In collaboration with Prof Peter Selby of Leeds we were successful in securing £2 million funding from NIHR to support a Diagnostic Evaluation Centre.

Biomarker Discovery
The Group participates in national collaborations to establish novel markers of disease progression in viral hepatitis including HCV Research UK.

This MRC funded project, led by Prof John McLaughlin in Glasgow and Prof Will Irving in Nottingham will collect 10,000 samples from patients with chronic HCV to permit the study of the association between host and viral genomic markers with disease severity, progression and treatment outcome.

With a consortium led by Prof Deenan Pillay we have recently been granted £5.9 million to study the impact of viral genetics on host responses in viral hepatitis.

Clinical trials
The Group leads and participates in clinical trials of new treatments for viral hepatitis C and B and liver fibrosis.

Recognizing the importance of both academic led and contract commercial clinical trials in the translational pathway we seek to play an active role in the conduct and delivery of clinical trials at all phases, to bring new treatments and test to the benefit of patients in our service.

We work actively with the Local Clinical Research Network and currently provide the clinical leadership for Hepatology and Division 2 of the Central and East London LCRN.

Immune & Cholestatic Liver Disease

PI: Dr Douglas Thorburn

PI: Dr Aileen Marshall

PI: Prof Stephen Pereira

Members

Dr Natascha Cieplik MD, Clinical Research Fellow
Mr Giuseppe Mazza MBs, PhD

UCL Collaborations:

Prof Massimo Pinzani

Prof William Rosenberg

Prof David Sansom (Institute of Immunology & Transplantation)

Prof Hans Stauss (Institute of Immunology & Transplantation)

Dr John Timms  (Institute for Women's Health)

Dr Pratima Chowdary (Research Department of Haematology)

External Collaborations:

Primary Sclerosing Cholangitits (PSC)

International PSC Study Group

Norwegian PSC Research Centre

UK PSC Consortium

Primary Biliary Cirrhosis (PBC)

UK PBC Consortium

Research interests:

  • Predicting prognosis in primary sclerosing cholangitis
  • Predicting/Early detection of carcinoma in primary sclerosing cholangitis
  • Coagulation in cholestatic liver disease
  • Evaluating new treatments in immune and cholestatic liver disease
  • Recurrent PSC following liver transplant

UCL Research Staff & Development Programme

We have the pleasure of introducing you to the new bespoke UCL Research Staff Development Programme (RSDP), organised centrally through HR Organisational Development.

The RSDP is aimed at supporting the development of all UCL research staff at various levels in their current research roles and in preparation for future careers. It focuses on developing research skills in becoming independent researchers, as well as professional and personal skills necessary for different career stages or sectors, academic or non-academic.

You can see below a few of the forthcoming events, or you can go directly to the RSDP Course Calendar and book your place.  These are some of the courses available, and more will be advertised throughout the year.